Impact of Outpatient Diuretic Infusion Therapy on Healthcare Cost and Readmissions

Nandini Nair MD, PhD, EMHL, Nandini Ray MBA, Pavida Pachariyanon MD, Ryan Burden MD, MBA, and Nicholas Skeen MBA

1Division of Cardiology, Department of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, USA
2University Medical Center, Lubbock, TX, USA

ABSTRACT

Background and Objectives: Heart failure (HF) is a complex syndrome with multiple etiologies resulting in impaired ventricular filling or pumping of blood. HF is as a major public health concern that leads to significant morbidity and mortality resulting in an enormous financial burden on the healthcare system. The study objectives were to assess the 30-day hospital readmission rates and its financial impact on the hospital.

Methods: The study was a retrospective single-center analysis of decoded data of all HF patients admitted to an outpatient diuretic infusion program. Adult patients who were readmitted to the hospital within 30 days despite guideline derive medical therapy were included if they were enrolled in the outpatient diuretic infusion clinic. Adult patients who were included in this study received a furosemide dose of 40 mg intravenously (infusion over 3 hours) at the clinic visit. Patients whose clinical signs/symptoms improved and remained stable in consequent visits were eventually discharged from the clinic. Financial impact was assessed using data obtained from the hospital administration on cost of HF readmissions.

Results: The results show a 30-day hospital readmission rate at 6–9% in the years analyzed (n=56) with a net savings of $562,815 to $736,560 per year.

Conclusions: This treatment strategy has no detrimental effects in addition to generating substantial financial savings. It appears to be a useful addition to the existing medical treatment regimens chronic HF patients.

Keywords: Outpatient diuretic therapy; Heart failure, diastolic; Heart failure, systolic; Heart failure; Hospital readmissions

INTRODUCTION

Heart failure (HF) is a complex syndrome with multiple etiologies resulting in impaired ventricular filling or pumping of blood. HF is associated with several symptoms such as dyspnea, fatigue, and peripheral/pulmonary edema. 6.2 million adults currently carry a diagnosis of HF in the United States. An estimated $30.7 billion was spent in 2012 due to the rising cost of healthcare services and medications and the consequent missed days of work secondary to HF. HF is as a major public health concern that leads to significant morbidity and mortality resulting in an enormous financial burden on the healthcare system mainly...
due to the chronicity of the disease. Globally, individuals over the age of 65 contribute to the most rapidly expanding population demographic. Such an increase is due to improved survival following myocardial infarctions and more efficient management of chronic conditions such as atherosclerosis, hypertension and diabetes mellitus. HF incidence increases significantly with age as a result of such advancements available in today's medicine.

HF results in the inability of the heart muscles to effectively supply blood throughout the body and leads to congestion and fluid accumulation. The generally accepted form of management involves the use of diuretic therapy, most often loop diuretics such as furosemide due to its effectiveness in treating decompensated HF, to relieve fluid overload. Deteriorating renal function, diuretic resistance, and electrolyte imbalance all influence the effectiveness of loop diuretics. Loop diuretics are widely accepted as the main form of treatment in patients with decompensated HF at the present time. However, there is no general consensus regarding the preferred mode of loop diuretics administered intravenously.

Although hospitalization due to HF has declined over time since 1995, individuals with underlying chronic conditions, such as diabetes mellitus and hypertension, appear to experience higher rates of morbidity and mortality due to the disease. As a result, it is of utmost importance to continue developing preventive strategies to help combat the disease and the subsequent financial burden for at-risk populations. The high costs associated with HF stem from poor discharge planning due to lack of communication/coordination of post discharge home care. Such gaps in care coordination becomes one of the leading causes of hospital readmissions. A solution to this problem would be to improve care and reduce costs. This involves shifting from the focus on providing high-intensity, expensive inpatient care to preventing, coordinating, and managing the illness in outpatient or primary care settings.

Several small studies have demonstrated the value of utilizing outpatient diuretic infusion clinics for high-risk patients with decompensated HF without the increased risk of harm. Existing studies have shown the benefit of outpatient diuretics. In a prospective analysis of diuretic infusions in the outpatient setting versus a brief hospitalization, the patients who received diuretics in a clinic had significantly lower 30-day readmission rates and a consequent financial benefit. A prospective study with a standardized protocol of biweekly infusions for 1 month noted a significant decrease in the 30-day hospital readmission rates. Other small studies have shown weight loss but no significant change in renal function. Our study is a single center retrospective analysis which attempts to address medical and financial benefits of outpatient furosemide infusion therapy across a four-year period from 2017–2020. Lowering cost is an important aspect in today’s healthcare economics in the United States because greater than 28% 30-day readmissions in the Medicare population will lead to a 3% penalty on all DRGs (Diagnosis related Groups). Additionally, frequent readmissions increase mortality in the HF population.

**METHODS**

**Study design**

An observational retrospective single-center analysis of decoded data of all HF patients between the ages of 18 and 89 years of age who received outpatient furosemide infusion therapy was used to identify the impact of outpatient furosemide treatment on 30-day
readmissions. We also sought to understand the financial impact of this therapy on 30-day readmissions. The study was conducted using patient data from January 2017 to December 2020. This study was approved by Institutional Review Board (IRB) at Texas Tech Health Sciences Center, Lubbock, TX. A total of 56 HF patients referred to the Texas Tech University Health Sciences Center, Center for Cardiovascular Health in Lubbock, Texas, USA for outpatient furosemide infusion therapy were included in this study. The following inclusion / exclusion criteria were used to select patients.

Inclusion criteria: Patients who were ≥18 years of age who were readmitted to the hospital within 30 days despite guideline derive medical therapy were included in the study.

Exclusion criteria: Patients who could not ambulate independently were excluded from the infusion clinic and the study for logistic reasons within the clinic setting.

Ethical consideration
All data were de-identified and stored securely on encrypted devices accessible only to study investigators in accordance with institutional policies. None of the data analyzed contained individually identifiable information. This study was approved by the Institutional Review Board (IRB) at Texas Tech health Sciences Center, Lubbock, TX 79430.

Study procedure
Adult patients who were included in this study received a furosemide dose of 40 mg intravenously as an infusion over a 3-hour period at the clinic visit. All laboratory values for complete blood count (CBC), complete metabolic panel (CMP) and coagulation parameters were obtained at each visit. The patients were monitored in a full telemetry unit, weights were recorded at the beginning and end of the visit. The patients were observed for 2 hours post infusion before they were discharged home. The frequency of clinic visits for infusion depended on the laboratory values and clinical signs/symptoms of patients at each visit. The visit frequency was hence widely varied from once every week to once every 4–6 weeks depending on the acuity of the patient at the previous visit. Patients whose laboratory values and clinical signs/symptoms improved and remained stable in consequent visits were spaced out and eventually discharged from the clinic. This clinic was used exclusively for chronic disease management in hemodynamically stable patients.

Clinical variables
The clinical characteristics of patients that were extracted for this study included the comorbidities and demographics (age, gender, and race). The vital signs such as blood pressure, heart rate, body weight loss post-infusion and post-treatment and home medications and laboratory parameters such as CBC, CMP, prothrombin time (PT), partial thromboplastin time, and international normalized ratio were monitored at every visit to the clinic.

Financial (economic burden) analysis
The hospital is subjected to CMS penalties for exceeding thresholds for HF readmissions for a 3-year average. From the hospital analysis of data, the chronic HF report is generated which indicated the hospital loss per admitted patient at $1,064 and the cost avoided per readmission computed from the hospital as $421. The net annual savings was therefore calculated by adding the annual avoidance cost to the annual savings. The annual savings is the amount generated when patients are not admitted to the hospital and annual avoidance cost is another entity generated by the hospital in addition to the savings generated by
preventing an admission. Therefore, the sum of the annual savings and annual avoidance costs give rise to the net annual savings.

The data obtained from the patients regarding the number of cases per month, the number of readmissions per month, the savings per patient of $1,064.00 due to prevented readmissions, and the cost avoided per readmission of $421.00, were entered into a data sheet on Microsoft Excel. The data were then coded to calculate average readmission rates, total monthly and annual savings, average savings per month by year, average savings per month across the four-year period, total monthly and annual avoidance, average avoidance per month by year, average avoidance per month across the four-year period, and the sum of the net savings and avoidance, along with the associated standard deviation and standard error calculations. The avoidance cost data was permuted as per existing hospital data. A p value of <0.05 was considered significant.

A discount analysis of the net present value (NPV), internal rate of return (IRR), and the profitability index was then performed using a discount rate of 5%, a period of 4 years during which the Center for Cardiovascular Health has administered furosemide infusion therapy for HF patients, an initial cash outflow based on investment values provided from fiscal year (FY) 2020, including medical supplies/equipment cost, infusion pharmacy costs, facilities (communications), and annual nurse salary, and cash inflows based on the total annual savings accrued per year from prevented readmissions from 2017 to 2020. The NPV, or the time series of the sum of the incoming and outgoing cash flows, was used to determine the financial viability of the project. The IRR was used to estimate the profitability of potential investments and is the discount rate at which the NPV of all cash flows is equal to zero. The profitability index was used to measure the attractiveness of the project.

Additionally, a single-factor ANOVA test was performed to determine whether there was sufficient evidence to conclude that the means of savings from prevented readmissions were equal across years to further explain the financial viability of the clinic. A data analysis tool pack called the “Real Statistics Resource Pack” for Excel was used to conduct the Kruskal-Wallis test (a non-parametric test) This has been done in addition to a one-way ANOVA.

**RESULTS**

**Characteristics of study patients**

Characteristics of the study cohort are shown in Table 1. The study population comprised of 25 patients with HF with reduced ejection fraction (HFrEF) and 31 patients with HF with preserved ejection fraction (HFrEF). The HFrEF patients had an ejection fraction (EF) of <35% and those with HFrEF had an EF of >50%. Table 1 describes the baseline characteristics of the two groups of patients. Both HFrEF and HFrEF patients have comparable rates of morbidity and mortality with some studies reporting slightly lower mortality rates in HFrEF patients.

The HFrEF patients had a significantly higher body mass index, systolic blood pressure, left ventricular hypertrophy. A higher number of HFrEF patients has obstructive sleep apnea on continuous positive airway pressure (CPAP). With reference to laboratory values the HFrEF patients had a higher hematocrit (Hct) and Sodium (Na) levels. The HFrEF patients had higher pulmonary pressures. A higher number of HFrEF patients had no CPAP though
Table 1. Baseline characteristics of study population

| Variables                | HFrEF† (n=25) | HFrEF‡ (n=31) | p value |
|--------------------------|---------------|---------------|---------|
| Age (years)              | 59 (50–69)    | 65 (54–72)    | 0.145   |
| Female gender            | 20%           | 39%           | 0.13    |
| Ethnics                  |               |               |         |
| Caucasian                | 32%           | 29%           | 0.78    |
| Hispanic                 | 56%           | 67%           | 0.78    |
| Black                    | 12%           | 10%           | 0.8     |
| Weight (kg)              | 105 (84–125)  | 128 (107–148) | 0.021*  |
| BMI (kg/m²)              |               |               |         |
| Obesity                  |               |               |         |
| Underweight              | 0.00%         | 0.00%         |         |
| Normal                   | 12.00%        | 0.00%         |         |
| Overweight               | 28.00%        | 3.20%         | 0.017*  |
| Obesity class I          | 12.00%        | 22.60%        | 0.03*   |
| Obesity class II         | 16.00%        | 22.60%        | 0.032*  |
| Obesity class III        | 32.00%        | 51.60%        | 0.02*   |
| NYHA                     |               |               |         |
| I                        | 0%            | 0%            |         |
| II                       | 20%           | 3.20%         | 0.018*  |
| III                      | 56.00%        | 71.00%        | 0.023*  |
| IV                       | 24%           | 25.80%        | 0.7     |
| SBP (mmHg)               | 118 (109–115) | 133 (119–138) | 0.004*  |
| DBP (mmHg)               | 73 (65–79)    | 72.5 (61–78)  | 0.207   |
| Afib/PAF                 | 32%           | 22.60%        | 0.429   |
| CKD stage 3,4            | 59%           | 56%           | 0.65    |
| T2DM                     | 56%           | 67.70%        | 0.357   |
| HTN                      | 84%           | 96.80%        | 0.096   |
| Dyslipidemia             | 92%           | 100%          | 0.2     |
| Stroke/TIA               | 12%           | 9.70%         | 0.78    |
| PHT due to LHD           |               |               |         |
| Mild                     | 16.00%        | 16.10%        | 0.34    |
| Moderate                 | 44.00%        | 35.50%        | 0.4     |
| Severe                   | 0.00%         | 3.20%         | 0.47    |
| COPD                     | 16.00%        | 19.40%        | 0.745   |
| CAD                      | 56%           | 45%           | 0.42    |
| OSA                      |               |               |         |
| OSA, no CPAP             | 84%           | 22.60%        | 0.015*  |
| OSA, on CPAP             | 16%           | 54.80%        | 0.01*   |
| Unknown                  | 0%            | 22.60%        | 0.015*  |
| Home medications         |               |               |         |
| Furosemide               | 72%           | 80.60%        | 0.446   |
| Torsemide                | 24.00%        | 16.10%        | 0.461   |
| Bumetanide               | 4.00%         | 3.20%         | 0.877   |
| Metolozane               | 0.00%         | 6.00%         | 0.196   |
| Chlorothiazide           | 28%           | 16.10%        | 0.282   |
| HCTZ                     | 0.00%         | 6.50%         | 0.196   |
| ACEI/ARB                 | 68%           | 67%           | 0.802   |
| Sacubitril/Valsartan     | 52.00%        | 3.20%         | 0.0001* |
| Aldosterone antagonist   | 20.00%        | 3.20%         | 0.044*  |
| Beta-blockers            | 88%           | 83.90%        | 0.661   |
| Digoxin                  | 4.00%         | 0.00%         | 0.269   |
| Nitrate                  | 16.00%        | 25.80%        | 0.374   |
| Hydralazine              | 12.00%        | 19.40%        | 0.456   |
| NDCCB                    | 4.00%         | 3.20%         | 0.877   |
| DCCB                     | 4.00%         | 25.80%        | 0.027*  |
| Sildenafil               | 28%           | 6.50%         | 0.029*  |
| Home milrinone           | 4.00%         | 0.00%         | 0.261   |
| ICD                      | 20%           | 0.00%         | 0.009*  |
| CRT                      | 19.20%        | 0%            | 0.009*  |
| Wearable defibrillator   | 24%           | 0%            | 0.019   |
| LVIDD (cm)               | 6.1 (5.5–6.6) | 5.2 (4.7–5.4) | 0.001*  |

(continued to the next page)
they carried a diagnosis of OSA. The medication regimen showed that a higher number of patients were on Sacubitril/Valsartan, and aldosterone antagonists as expected with a low the HFrEF.

19) The number of HFrEF patients on sildenafil was higher consistent with higher pulmonary pressures in this group. Consistent with guidelines all patients with a intracardiac defibrillator, wearable defibrillator, cardiac resynchronization therapy were in the HFrEF group.

19) Higher left ventricular internal end diastolic dimension, left ventricular end systolic dimension and severe left atrial enlargement were more common in the HFrEF group as expected with dilated hearts and low EF. BNP was higher in the HFrEF patients as compared with those with HFpEF which is consistent with existent data.

On longitudinal analysis (3–12 months of outpatient diuretic therapy) the renal function remained stable between and within the groups. Creatinine was 1.8±0.2 p=0.2, 2.0±0.3 p=0.9 respectively. The liver function tests (aspartate aminotransferase [9±2 p=0.2, 13±3 p=0.3 respectively], alanine aminotransferase (15±4 p=0.3, 17±3 p=0.2 respectively), total bilirubin 0.9±0.2 p=0.7, 1.2±0.3 p=0.2 respectively), were stable throughout the course of longitudinal follow up of 3–12 months.

**Financial (economic burden) analysis**

This observational study focused on the retrospective analysis of 30-day congestive HF readmissions for patients who received outpatient Furosemide infusion therapy between the years 2017 and 2020 and the savings associated with the number of prevented readmissions within 30 days of receiving the treatment. Across the four-year study period, the average 30-day congestive heart failure (CHF) readmission rates following outpatient furosemide therapy

---

**Table 1. (continued) Baseline characteristics of study population**

| Variables | HFrEF† (n=25) | HFpEF‡ (n=31) | p value |
|-----------|---------------|---------------|---------|
| LVSD (cm) | 1.0 (0.9–1.1) | 1.0 (0.9–1.1) | 0.491   |
| LVH       |               |               |         |
| Mild      | 12%           | 12.90%        | 0.702   |
| Moderate  | 4%            | 9.70%         | 0.029*  |
| RV dysfunction | 44%     | 9.70%         | 0.003*  |
| LAE       |               |               |         |
| Mild      | 56%           | 38%           | 0.021*  |
| Moderate  | 20%           | 16.10%        | 0.11    |
| Severe    | 12%           | 0%            | 0.001*  |
| Hb (g/dL) | 14.3 (11.4–16.0) | 12.8 (10.3–13.8) | 0.081 |
| Hct %     | 42.3 (35.5–47.6) | 38.8 (32–42) | 0.039* |
| Na (mEq/L)| 139 (136.5–141.5) | 141 (139–142.3) | 0.024* |
| K (mEq/L) | 4.3 (4.1–4.6) | 4.3 (4.0–4.5) | 0.798   |
| BUN (mg/dL)| 22 (15.0–34.0) | 26.5 (16.8–40.0) | 0.364 |
| Cr (mg/L) | 1.2 (1.1–1.9) | 1.4 (1.0–1.7) | 0.856   |
| GFR       | 59.9 (37.3–71.7) | 52.7 (34.8–77.0) | 0.717  |
| Albumin (g/dL) | 4.2 (4.1–4.4) | 4.0 (3.8–4.2) | 0.055  |
| BNP (pg/mL)| 3,022 (1,097–7,448) | 991 (207–2,399) | 0.001* |

BMI = body mass index; NYHA = New York Heart Association; SBP = systolic blood pressure; DBP = diastolic blood pressure; CKD = chronic kidney disease; T2DM = type 2 diabetes; HTN = hypertension; TIA = transient ischemic attack; PHT = pulmonary hypertension; LHD = left heart disease; COPD = chronic obstructive pulmonary disease; CAD = coronary artery disease; OSA = obstructive sleep apnea; CPAP = continuous positive airway pressure; HCTZ = hydrochlorothiazide; ACEI = angiotensin-converting-enzyme inhibitor; ARB = angiotensin II receptor blocker; NDCCB = non-dihydropyridine calcium channel blocker; DCCB = dihydropyridine calcium channel blocker; ICD = intracardiac defibrillator; CRT = cardiac resynchronization therapy; LVIDD = left ventricular internal end diastolic dimension; LVSD = left ventricular systolic dysfunction; LVH = left ventricular hypertrophy; RV = right ventricular; LAE = left atrial enlargement; Hb = hemoglobin; Hct = hematocrit; BUN = blood urea nitrogen; GFR = glomerular filtration rate; BNP = brain natriuretic peptide.

*p<0.05; †Heart failure with reduced ejection fraction; ‡Heart failure with preserved ejection fraction.
were 9% in 2017, 6% in 2018, 7% in 2019, and 8% in 2020 (Figure 1A). Readmission rates by month across the 2017–2020 study period ranged from 3% to 12% (Figure 1B).

During this study period from 2017–2020, the total annual savings ranged from $400,000 to $530,000 by utilizing a value for savings per patient of $1,064.00 (Table 2, Figure 2A-D).

Figure 1. (A) Graph shows the average 30-day readmission rate for the years 2017 to 2020. (B) Graph shows the average 30-day readmissions per month for the years 2017 to 2020. Error bars denote the variations per month for each year.

Figure 2. (A) Graph shows total annual savings plotted against the years analyzed 2017 to 2020. (B) Graph shows the average savings per month plotted per month over the years 2017 to 2020. (C) Graph shows average savings per month for the years 2017 to 2020. (D) Graph shows average savings per month for the years 2017 to 2020. Error bars in (C and D) show variations per month for each year.
The total annual avoidance ranged from $150,000 to $210,000 by utilizing a value for cost avoided per readmission of $421.00 (Table 2, Figure 3A-D). The net savings were calculated by combining the total annual savings and the total annual avoidance values (Table 2).

The discount analysis utilized a discount rate of 5%, a study time period of 4 years, a cash outflow of $116,155 based on investment values provided from FY 2020, and a cash inflow based on the total annual savings accrued per year from prevented readmissions of $403,256 in 2017, $527,744 in 2018, $525,616 in 2019, and $497,952 in 2020 (Table 3). These values were used to calculate the NPV of $1,610,290, an IRR of 369%, and a profitability index of 14.9 (Table 3).

A single-factor ANOVA test was performed using the total savings per month across the four-year study period to determine if there was sufficient evidence to conclude that the means of savings from prevented readmissions are not equal across the study years. At least

![Figure 3](https://e-heartfailure.org/doi/10.36628/ijhf.2021.0031)
one of the population means is different from the others as there is a significant difference in the means of savings from prevented readmissions between the years 2017 and 2018, 2017 and 2019, and 2017 and 2020 (Figure 4). We have also performed a Kruskal-Wallis test, (a non-parametric test) (Table 4) in addition to the one-way ANOVA test which was used to account for the violations of the assumptions of normality in a single-factor ANOVA test using the Real Statistics Resource Pack in Microsoft Excel. Because the Kruskal-Wallis Test (Table 4) showed a significant difference between the medians of savings from prevented readmissions between the years 2017 and 2020, this demonstrates that at least one of the group populations is dominant over the others. As a result, a pairwise comparison using a single-factor ANOVA test was utilized to pinpoint the exact differences between groups as seen in Figure 4.

From the financial standpoint an NPV of $1,610,290.9 was calculated across the time period. This large positive value indicates the positive financial viability of the project. The IRR estimates the profitability of potential investments and is essentially the discount rate at which the NPV of all cash flows is equal to zero. An IRR of 369% was calculated. If the IRR on a project exceeds the cost of capital, net cash flows would be higher. The profitability index is a measure of the project’s success. A high profitability index (greater than 1) of 14.86 indicates that this project is successful.

The significant difference in the means of savings from prevented readmissions between the years 2017–2018, 2017–2019, and 2017–2020 from the single-factor ANOVA and the Kruskal-Wallis tests indicates that the outpatient diuretic infusion clinic has become more efficient since its inception in 2017. The nonsignificant difference between the years 2018–2019, 2018–2020, and 2019–2020 indicate that the clinic has maintained steady inflows and savings since then.
DISCUSSION

This is a single center observational retrospective study which addresses the role of outpatient diuretic therapy in reducing 30-day hospital readmissions for chronic disease management. The important medical aspects are that both HFrEF and HFpEF patients appear to benefit from this treatment with no significant worsening of kidney function or liver function. This approach can potentially lead to a reduction in healthcare costs, amongst other benefits, such as possible improvement in quality of life and reduction in mortality as they remain outside the hospital. The definitive effects of the outpatient diuretic therapy on quality of life and reduction in mortality were not investigated in this study and will need future investigation. This study shows a much lower 30-day readmission rate in this cohort as compared to the average 30-day hospital readmissions which is around 25% at a national level. Allowing more healthcare institutions to adopt outpatient diuretic infusion clinics for high-risk CHF patients may pave the way for a new model in healthcare which could help reduce the number of hospital admissions due to this disease. This is especially important in patients with both chronic kidney disease and chronic CHF with symptom burden, hospitalization, and mortality increase.21 Outpatient diuretic clinics will help chronic disease management in improving clinical and financial benefits. This concept needs further investigation in a randomized clinical trial.22
The NPV, IRR, and PI values calculated for this clinic are very high, and consistent with the overall high profitability of the outpatient diuretic infusion clinic. Some factors that may have contributed to this high profitability include the already existing infrastructure of the clinic prior to setting up this outpatient therapy, reduced hospital readmissions, an established patient base, and the effectiveness of the treatment.

In this small study there appears to be no difference in the readmission rates of patients with HFrEF versus HFpEF who are treated in the outpatient diuretic clinic. This suggests that the cost savings is essentially the same between the two groups because the financial impact is computed from the readmission rates. This finding needs to be investigated and validated in larger studies.

It is interesting that on computation of our savings we get an average of approximately $681,986 as annual net savings and when calculated per patient annually it appears to be $12,718. This is in close agreement with the published value of $12,113 per patient annually. This suggests that outpatient diuretic therapy produces a standard financial benefit which needs to be validated in larger studies.

The clinical outcome addressed here is 30-day readmission rate which is 6–9% for the years analyzed (2017–2020). This is considerably lower than the average 30 day readmission rates noted in the United States which is 25%. There was no difference in readmission rates between the two groups examined (HFrEF and HFpEF).

The main causes of increased medical costs during inpatient admissions are due to hospital charges for in patient stay, tests ordered by the different teams because HF management is a multidisciplinary approach and increase length of stay. All of these costs can be avoided if efficient management occurs in the outpatient setting. Due to organizational confidentiality issues more granular details of inpatient costs were not available for analysis. Therefore, the available data were used to calculate financial benefits for the outpatient management presented in this paper.

This is the first report that approaches the role of an outpatient diuretic treatment from a medical and financial perspective in terms of its impact on healthcare costs with important medical significance. However, the study has its limitations in that it is a retrospective study and a single center experience.

In summary the financial analysis of this pilot study shows its feasibility and needs to be further investigated in larger populations. From the medical standpoint it is a safe treatment which does not have a detrimental effect on the kidney and liver function as well as metabolites which are reviewed at every visit. This approach should be tested in larger populations to establish its role in chronic disease management of HF.

REFERENCES

1. Snipelisky D, Chaudhry SP, Stewart GC. The many faces of heart failure. Card Electrophysiol Clin 2019;11:11-20.
2. Virani SS, Alonso A, Benjamin EJ, et al. Heart disease and stroke statistics—2020 update: a report from the American Heart Association. Circulation 2020;141:e139-506.

3. Benjamin EJ, Munter P, Alonso A, et al. Heart disease and stroke statistics—2019 update: a report from the American Heart Association. Circulation 2019;139:e56-528.

4. Shah N, Madaníeh R, Alkan M, Dogar MU, Kosmas CE, Vittorio TJ. A perspective on diuretic resistance in chronic congestive heart failure. Ther Adv Cardiovasc Dis 2017;11:271-8.

5. Mullens W, Damkan K, Harjola VP, et al. The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2019;21:137-55.

6. Real J, Cowles E, Wierzbicki AS; Guideline Committee. Chronic heart failure in adults: summary of updated NICE guidance. BMJ 2018;362:k3646.

7. Alghalayini KW. Effect of diuretic infusion clinic in preventing hospitalization for patients with decompensating heart failure. SAGE Open Med 2020;8:2050312120940094.

8. Honigberg MC, Patel RB, Pandey A, et al. Trends in hospitalization for heart failure and ischemic heart disease among US adults with diabetes. JAMA Cardiol 2021;6:354-7.

9. Sanghavi D, George M, Alawa N, et al. Treating congestive heart failure and the role of payment reform. The Merkin Series on Innovation in Care Delivery [Internet]. Washington, D.C.: The Brookings Institution; 2014 [cited 2021 May 16]. Available from: https://www.brookings.edu/research/treating-congestive-heart-failure-and-the-role-of-payment-reform/.

10. Makadia S, Simmons T, Augustine S, et al. The diuresis clinic: a new paradigm for the treatment of mild decompensated heart failure. Am J Med 2015;128:527-31.

11. Hamo CE, Abdelmoneim SS, Han SY, et al. OUTpatient intravenous LASix Trial in reducing hospitalization for acute decompensated heart failure (OUTLAST). PLoS One 2021;16:e0253014.

12. Shah RA, Subban V, Lakshmanan A, et al. A prospective, randomized study to evaluate the efficacy of various diuretic strategies in acute decompensated heart failure. Indian Heart J 2014;66:309-16.

13. CMS.gov. Hospital Readmissions Reduction Program (HRRP). Baltimore: CMS.gov; 2020 [cited 2021 July 4]. Available from: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/Readmissions-Reduction-Program.

14. Setoguchi S, Stevenson LW, Schneeweiss S. Repeated hospitalizations predict mortality in the community population with heart failure. Am Heart J 2007;154:260-6.

15. Lee DS, Gona P, Vasan RS, et al. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the framingham heart study of the national heart, lung, and blood institute. Circulation 2009;119:3070-7.

16. Gapenski LC, Reiter KL. The capital structure and the cost of capital. In: An Introduction to Accounting and Financial Management. 6th ed. Chicago: Health Administration Press; 2016. p.475-516.

17. Henkel DM, Redfield MM, Weston SA, Gerber Y, Roger VL. Death in heart failure: a community perspective. Circ Heart Fail 2008;1:91-7.

18. Hobbis FD, Roalfé AK, Davis RC, Davies MK, Hare R; Midlands Research Practices Consortium (MidReC). Prognosis of all-cause heart failure and borderline left ventricular systolic dysfunction: 5 year mortality follow-up of the Echocardiographic Heart of England Screening Study (ECHOES). Eur Heart J 2007;28:1128-34.

19. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013;128:e240-327.
20. Kanagala P, Arnold JR, Singh A, et al. Characterizing heart failure with preserved and reduced ejection fraction: an imaging and plasma biomarker approach. PLoS One 2020;15:e0232280.

21. Romero-González G, Ravassa S, González O, et al. Burden and challenges of heart failure in patients with chronic kidney disease. A call to action. Nefrologia (Engl Ed) 2020;40:223-36.

22. Wierda E, Dickhoff C, Handoko ML, et al. Outpatient treatment of worsening heart failure with intravenous and subcutaneous diuretics: a systematic review of the literature. ESC Heart Fail 2020;7:892-902.